Hepatic Encephalopathy Clinical Trials

A listing of Hepatic Encephalopathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality (APACHE)

This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the …

plasma exchange
  • 113 views
  • 22 Oct, 2022
  • 28 locations
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

fibrosis
  • 0 views
  • 21 Oct, 2022
  • 1 location
Hepatic Encephalopathy Prevention With Polydextrose After TIPS: Pilot Study (POEME) (POEME)

TIPS is a standard for the treatment of portal hypertension related complications. However, it remains at risk of HE after TIPS (around 40% the first year). Dysbiosis plays a key role in pathophysiology of HE. Polydextrose (PDX) is consider as a prebiotic. Preliminary studies showed that PDX: modified gut microbiota, …

ascites
cirrhosis
encephalopathy
hypertension
  • 0 views
  • 04 Oct, 2022
  • 1 location
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are high. Hyperammonemia contributes significantly to encephalopathy and occurs because of impaired

ct scan
encephalopathy
protein supplement
liver disease
cirrhosis
  • 38 views
  • 07 Oct, 2022
  • 1 location
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.

rifaximin
meld score
liver disease
encephalopathy
hepatic impairment
  • 328 views
  • 07 Oct, 2022
  • 21 locations
A Trial to Improve Quality of Life in People With Cirrhosis - the Michigan Kristalose Trial

not been diagnosed with Hepatic Encephalopathy (HE), but report reduced quality of life.

lactulose
encephalopathy
  • 0 views
  • 24 Oct, 2022
  • 1 location
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)

overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by the presence of medically controlled ascites.

rifaximin
liver disease
cirrhosis
encephalopathy
ascites
  • 1 views
  • 10 Oct, 2022
  • 0 views
  • 13 Oct, 2022
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.

corticosteroids
encephalopathy
liver injury
mediators
  • 0 views
  • 04 Oct, 2022
  • 11 locations
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Background Chronic hepatitis C infects the liver. It may scar the liver. This is called cirrhosis and may lead to liver cancer or death. Current chronic hepatitis C treatments cure most people. But some keep getting complications even after it is cured. Researchers want to study why. Objective To study …

antiviral drugs
hemoglobin a1c
glycosylated hemoglobin
hemophilia
liver cancer
  • 23 views
  • 07 Oct, 2022
  • 1 location